SOURCE: Gene Express, Inc.

January 16, 2008 09:00 ET

Gene Express's David Lester, Ph.D. Featured Speaker on Biomarkers at the 6th Annual Partnering With Central Labs, ECG and Imaging Labs Event

TOLEDO, OH--(Marketwire - January 16, 2008) - Gene Express, Inc. today announced that David S. Lester, Ph.D., Senior Vice President of Strategy and Corporate Development, will be a featured speaker at the 6th Annual Partnering with Central Labs, ECG and Imaging Labs in Orlando, FL, January 23-25.

Dr. Lester will be presenting during the pre-conference workshop entitled "Operational Biomarker and Assay Transfer," and the title of his lecture is "Biomarkers: From Clinical Trial to Clinical Practice: The Patient Perspective and Economic Implications on Biomarker Development." Dr. Lester's presentation will focus on the value of the biomarker for the patient experience during clinical trials, the transfer of this approach to the clinical practice, and how this will impact the ROI of developing such tests. Additionally, Dr. Lester is one of the presenters for the Biomarker Track entitled "Operational Biomarker Development," and the title of his talk is "Biomarkers Development: from Discovery to Delivery." His presentation will focus on the delivery chain of biomarkers from clinical biomarker to the diagnostic.

To learn more about this event, please go to http://www.iirusa.com/centrallab/eventhome/21191.xml

David S. Lester received his Ph.D. in Biological Sciences from Northwestern University and has held positions at Harvard University Medical School, the Weizmann Institute of Science (Israel) and National Institute of Neurological Disorders and Stroke at the National Institutes of Health. He is currently serving as Senior Vice President at Gene Express, Inc. in charge of Strategy and Corporate Development. Dr. Lester is also President of Innovative Technologies for Health and Wellness (ITHW, Inc.). He has held executive positions, and played pivotal roles at Pfizer, in the Global Clinical Technology and Human Health Technologies Groups, as well as at Pharmacia Corp., and at the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). Dr. Lester's Research interests have included the incorporation of innovative technologies into clinical trials for the use of biomarkers or surrogate endpoints. He has an extensive publication record including five edited volumes. Dr. Lester is active in numerous professional societies and has a strong record in public science policy activities.

About the Annual Partnering with Central Labs, ECG and Imaging Labs Conference

The Central Labs, ECG and Imaging Labs conference brings small and large sponsors and lab partners together to build more efficient processes from the initial selection process through final database lock.

The paradigm shift for the lab industry from simple safety testing services to a more scientific and strategic global partner has demanded a change in the way the industry does business. This is the only forum to hear proven strategies to accomplish successful global partnerships through case studies using the latest scientific and technological advancements to respond to the changing industry.

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at www.geneexpressinc.com.

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information